← All Pulmatrix, INC filings

Pulmatrix, INC Form 4 insider transactions

Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.

NASDAQ
PULM
Pulmatrix, INC
425: Eos SENOLYTIX Presents Positive Preclinical Data
Eos SENOLYTIX reports positive preclinical results for its lead geropeptide candidate, PTC-2105, ahead of its merger with Pulmatrix.
NASDAQ
PULM
Pulmatrix, INC
425: Pulmatrix Merges with Eos SENOLYTIX for Anti-Aging Focus
Pulmatrix and Eos SENOLYTIX announce a definitive merger agreement to create a leading anti-aging biotechnology company, Eos SENOLYTIX, supported by $19 million in concurrent financings.
NASDAQ
PULM
Pulmatrix, INC
425: Pulmatrix Stockholders Greenlight Cullgen Merger, Await Key China Regulatory Approval
Pulmatrix, Inc. stockholders have overwhelmingly approved all proposals related to the previously announced merger with Cullgen Inc., including the issuance of shares, a reverse stock split, and an increase in authorized common stock, though the merger remains subject to China Securities Regulatory Commission (CSRC) approval.
NASDAQ
PULM
Pulmatrix, INC
425: Cullgen Initiates Phase 1 Trial for Novel Oral Pain Treatment, CG001419, Following Merger Agreement with Pulmatrix
Cullgen has begun dosing human subjects in a Phase 1 trial for its oral pan-TRK protein degrader, CG001419, aimed at treating acute and chronic pain, marking its second clinical program.